Liposomes-enabled cancer chemoimmunotherapy

Lele Zhang,Jiangpei Shi,Mao-Hua Zhu,Yanhu Huang,Qin Lu,Peng Sun,Hong-Zhuan Chen,Xing Lai,Chao Fang
DOI: https://doi.org/10.1016/j.biomaterials.2024.122801
IF: 14
2024-09-03
Biomaterials
Abstract:Chemoimmunotherapy is an emerging paradigm in the clinic for treating several malignant diseases, such as non-small cell lung cancer, breast cancer, and large B-cell lymphoma. However, the efficacy of this strategy is still restricted by serious adverse events and a high therapeutic termination rate, presumably due to the lack of tumor-targeted distribution of both chemotherapeutic and immunotherapeutic agents. Targeted drug delivery has the potential to address this issue. Among the most promising nanocarriers in clinical translation, liposomes have drawn great attention in cancer chemoimmunotherapy in recent years. Liposomes-enabled cancer chemoimmunotherapy has made significant progress in clinics, with impressive therapeutic outcomes. This review summarizes the latest preclinical and clinical progress in liposome-enabled cancer chemoimmunotherapy and discusses the challenges and future directions of this field.
What problem does this paper attempt to address?